SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-014229
Filing Date
2022-05-13
Accepted
2022-05-13 08:03:42
Documents
16
Period of Report
2022-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tpst-20220513.htm   iXBRL 8-K 40418
2 EX-99.1 q1228-kexhibit991.htm EX-99.1 25196
6 image_0a.jpg GRAPHIC 34814
7 picture4.jpg GRAPHIC 195946
8 picture5.jpg GRAPHIC 92626
  Complete submission text file 0001628280-22-014229.txt   656693

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tpst-20220513.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tpst-20220513_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tpst-20220513_pre.xml EX-101.PRE 13048
10 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20220513_htm.xml XML 11082
Mailing Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 22920307
SIC: 2834 Pharmaceutical Preparations